Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats

Abstract

The effects of the citrus bioflavonoid naringin were tested by using it as a supplement in a high-cholesterol diet. Male rats were fed for 42 days with a 1% (wt/wt) high cholesterol diet either with or without naringin-supplementation (0.1%, wt/wt) to study the effect on plasma lipid levels, hepatic lipid contents, hepatic enzyme activity, and the excretion of fecal neutral sterols. Naringin did not significantly alter the levels of plasma triglycerides, however, the levels of plasma cholesterol (3.80 ± 0.31 mmol/L vs. 2.61 ± 0.30 mmol/L, mean ± SE; p < 0.05) and hepatic cholesterol (70.3 ± 4.3 mg/g vs. 54.3 ± 3.8 mg/g, mean ± SD; p < 0.05) were significantly lowered compared to those of the control. HMG-CoA reductase (2487.0 ± 210.0 pmole/min/mg vs. 1879.0 ± 236.0 pmole/min/mg, mean ± SE; p < 0.05) and ACAT (806.0 ± 105.0 pmole/min/mg vs. 643.0 ± 80.0 pmole/min/mg, mean ± SE; p < 0.05) activities were both substantially lower in the naringin-supplemented group than in the control. The naringin supplementation markedly decreased the excretion of fecal neutral sterols (204.7 ± 28.5 mg/day) compared to the control (521.9 ± 53.9 mg/day). The combination of the inhibited HMG-CoA reductase (-24.4%) and ACAT (-20.2%) activities as a result of naringin supplementation could account for the decrease of fecal neutral sterols.